Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMM7Z6K)

Drug Name
CXA10 Drug Info
Indication
Disease Entry ICD 11 Status REF
Focal segmental glomerulosclerosis MF8Y Phase 2 [1]
Pulmonary arterial hypertension BB01.0 Phase 2 [2]
Cross-matching ID
TTD Drug ID
DMM7Z6K

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cysteines of Keap1 (KEAP1 Cysteines) TT3Z6Y9 KEAP1_HUMAN Inactivator [3]
Nuclear factor erythroid 2-related factor 2 (Nrf2) TTA6ZN2 NF2L2_HUMAN Activator [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Nuclear factor erythroid 2-related factor 2 (Nrf2) DTT NFE2L2 8.964 8.362 9.046 8.808
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Focal segmental glomerulosclerosis
ICD Disease Classification MF8Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Nuclear factor erythroid 2-related factor 2 (Nrf2) DTT NFE2L2 4.75E-12 -0.28 -0.58
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03422510) FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT04053543) CXA-10 Study in Subjects With Pulmonary Arterial Hypertension. U.S. National Institutes of Health.
3 The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017 Feb;9(1):41-56.